<section id="ct" class="section">
    <nav class="desktop">
        <a href="" ui-sref="MOA" class="moa">
            <i class="fas fa-atom"></i>
        </a>
        <a href="" ui-sref="CT" class="ct active">
            <i class="fas fa-users"></i>
        </a>
        <a href="" ui-sref="EFFICACY" class="efficacy">
            <i class="fas fa-chart-line"></i>
        </a>
        <a href="" ui-sref="SAFETY" class="safety">
            <i class="fas fa-exclamation-triangle"></i>
        </a>
        <a href="" ui-sref="DOSING" class="dosing">
            <i class="fas fa-prescription"></i>
        </a>
    </nav>
    <main class="trial-design">
    <div class="top">
        <a href="" ui-sref="PHASE-PK-ANALYSIS"><img src="assets/pfizer-logo.svg" alt="Pfizer Logo"></a>
        <h1>Tofacitinib pcJIA</h1>
    </div>
    <div class="content">
        <a href="" ui-sref="STUDY-DESIGN" class="back-btn">
            <i class="fas fa-arrow-circle-left"></i>
            <h5 class="ct-header">BACK</h5>
        </a>
        <h3 class="ct-header">BASELINE DISEASE CHARACTERISTICS</h3>
        <p>International, open-label Phase 1, multiple dose study evaluating
            pharmacokinetics, safety, and tolerability (N = 26)<sup>a</sup>
        </p>
        <div class="img-wrapper">
            <img src="assets/ct/trial-design.png" alt="Trial Design" />
        </div>
        <div class="tables">
        <div class="table">
            <h5>Key inclusion criteria</h5>
            <ul>
                <li>Age 2-&lt;18 years</li>
                <li>Active pcJIA (extended oligoarthritis, RF<sup>+/-</sup>, jPsA or ERA</li>
                <li>&geq; active joints at time of enrollment</li>
            </ul>
        </div>
        <div class="table gray">
            <h5>Key exclusion criteria</h5>
            <ul>
                <li>Systemic JIA</li>
                <li>Persistent oligoarthritis</li>
                <li>Undifferentiated JIA</li>
                <li>History of autoimmune disease or any condition affecting drug absorption</li>
            </ul>
        </div>
        <div class="table">
            <h5>Endpoints</h5>
            <p class="subheader">PK endpoints</p>
            <ul>
                <li>AUC<sub>tau</sub>(ng·h/mL)</li>
                <li>C<sub>max</sub>(ng/mL)</li>
                <li>T<sub>max</sub>(h)</li>
                <li>T<sub>1/2</sub>(h)</li>
                <li>CL/F (L/h)</li>
            </ul>
            <p class="subheader">Safety endpoints:</p>
            <ul>
                <li>Adverse Events</li>
                <li>Vital Signs</li>
                <li>Lab Data</li>
            </ul>
        </div>
        </div>
        <div class="footnotes">
            <ol>
                <li>Children aged 2 to 6 weighing &lt;30 kg and those 6 to 18 weighing &lt;40 kg received oral solution, while children aged 6 to 18 weighing ≥40 kg received tablets, although oral solution (1 mg/mL suspension) was offered to those who preferred a solution to a tablet.</li>
            </ol>
            <p>ACR, American college of Rheumatology; APR, acute phase reactant; AUCtau, area under the plasma concertation time curve; BID, twice daily; CHAQ DI, child health assessment questionnaire disability index; CL/F, apparent systemic clearance; Cmax, maximum observed plasma concentration; ERA, enthesitis related arthritis; JIA, juvenile idiopathic arthritis; jPsA =juvenile psoriatic arthritis; pcJIA, polyarticular course juvenile idiopathic arthritis; Tmax, time of maximum concentration observed.</p>
            <p>Ruperto N, et al. Pediatr Rheumatol Online J. 2017;15:86.</p>
        </div>
    </div>
    </main>
</div>
<nav class="mobile">
    <a href="" ui-sref="MOA" class="moa">
        <i class="fas fa-atom"></i>
        <h5>MOA</h5>
    </a>
    <a href="" ui-sref="CT" class="ct active">
        <i class="fas fa-users"></i>
        <h5>Clinical Trials</h5>
    </a>
    <a href="" ui-sref="EFFICACY" class="efficacy">
        <i class="fas fa-chart-line"></i>
        <h5>Efficacy</h5>
    </a>
    <a href="" ui-sref="SAFETY" class="safety">
        <i class="fas fa-exclamation-triangle"></i>
        <h5>Safety</h5>
    </a>
    <a href="" ui-sref="DOSING" class="dosing">
        <i class="fas fa-prescription"></i>
        <h5>Dosing</h5>
    </a>
</nav>
</section>